참고문헌
- Ather MH, Abbas F, Faruqui N, Israr M, Pervez S (2008). Correlation of three immunohistochemically detected markers of neuroendocrine differentiation with clinical predictors of disease progression in prostate cancer. BMC Urol, 8, 21. https://doi.org/10.1186/1471-2490-8-21
- Berruti A, Dogliotti L, Mosca A, et al (2000). Circulating neuroendocrine markers in patients with prostate carcinoma. Cancer, 88, 2590-7. https://doi.org/10.1002/1097-0142(20000601)88:11<2590::AID-CNCR23>3.0.CO;2-D
- Bossuyt PM, Reitsma JB, Bruns DE, et al (2004). Towards complete and Accurate reporting of studies of diagnostic accuracy: the STARD initiative. Fam Pract, 21, 4-10. https://doi.org/10.1093/fampra/cmh103
- Emin EA, Gunduz A, Batum O, et al (2010). Pre-treatment and treatment-induced neuron-specific enolase in patients with small-cell lung cancer: an open prospective study. Arch Bronconeumol, 46, 364-9.
- Fizazi K, Cojean I, Pignon JP, et al (1998). Normal serum neuron specific enolase (NSE) value after the first cycle of chemotherapy: an early predictor of complete response and survival in patients with small cell lung carcinoma. Cancer, 82, 1049-55. https://doi.org/10.1002/(SICI)1097-0142(19980315)82:6<1049::AID-CNCR6>3.0.CO;2-9
- Greenberg AK, Lee MS (2007). Biomarkers for lung cancer: clinical uses. Curr Opin Pulm Med, 13, 249-55. https://doi.org/10.1097/MCP.0b013e32819f8f06
- Humez S, Monet M, Legrand G, et al (2006). Epidermal growth factor-induced neuroendocrine differentiation and apoptotic resistance of androgen-independent human prostate cancer cells. Endocr Relat Cancer, 13, 181-95. https://doi.org/10.1677/erc.1.01079
- Hvamstad T, Jordal A, Hekmat N, Paus E, Fossa SD (2003). Neuroendocrine serum tumour markers in hormone-resistant prostate cancer. Eur Urol, 44, 215-21. https://doi.org/10.1016/S0302-2838(03)00257-4
- Kamiya N, Akakura K, Suzuki H, et al (2003). Pretreatment serum level of neuron specific enolase (NSE) as a prognostic factor in metastatic prostate cancer patients treated with endocrine therapy. Eur Urol, 44, 309-14. https://doi.org/10.1016/S0302-2838(03)00303-8
- Kodet R, Kodetova D, Smelhaus V (1991). Tumors of the peripheral sympathetic nervous system in childhood. Immunohistochemical study. Cesk Patol, 27, 97-104.
- Li X, Asmitananda T, Gao L, et al (2012). Biomarkers in the lung cancer diagnosis: a clinical perspective. Neoplasma, 59, 500-7. https://doi.org/10.4149/neo_2012_064
- Lilleby W, Paus E, Skovlund E, Fossa SD (2001). Prognostic value of neuroendocrine serum markers and PSA in irradiated patients with pN0 localized prostate cancer. Prostate, 46, 126-33. https://doi.org/10.1002/1097-0045(20010201)46:2<126::AID-PROS1016>3.0.CO;2-7
- Massarelli G, Onida GA, Piras MA, et al (1999). Neuron-specific enolase (gamma enolase, gamma-gamma dimer) expression in Hodgkin's disease and large cell lymphomas. Anticancer Res, 19, 3933-8.
- Nakatsuka S, Nishiu M, Tomita Y, et al (2002). Enhanced expression of neuron-specific enolase (NSE) in pyothoraxassociated lymphoma (PAL). Jpn J Cancer Res, 93, 411-6. https://doi.org/10.1111/j.1349-7006.2002.tb01272.x
- Pejcic I, Vrbic S, Filipovic S, et al (2010). Significance of serum tumor markers monitoring metastases in carcinomas of unknown primary site. Vojnosanit Pregl, 67, 723-31. https://doi.org/10.2298/VSP1009723P
- Peshavaria M, Day INM (1991). Molecular structure of the human muscle-specific enolase gene (EN03). Biochem J, 275, 427-33.
- Ramage JK, Davies AH, Ardill J, et al (2005). Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours. Gut, 4, 1-16.
- Schmidt D, Harms D, Burdach S (1985). Malignant peripheral neuroectodermal tumours of childhood and adolescence. Virchows Arch A Pathol Anat Histopathol, 406, 351-65. https://doi.org/10.1007/BF00704304
- Song TJ, Choi YC, Lee KY, Kim WJ (2012). Serum and cerebrospinal fluid neuron-specific enolase for diagnosis of tuberculous meningitis. Yonsei Med J, 53, 1068-72. https://doi.org/10.3349/ymj.2012.53.6.1068
- Sung HJ, Cho JY (2008). Biomarkers for the lung cancer diagnosis and their advances in proteomics. BMB Rep, 41, 615-25. https://doi.org/10.5483/BMBRep.2008.41.9.615
- Wojcik E, Jakubowicz J, Skotnicki P, Sas-Korczynska B, Kulpa JK (2010). IL-6 and VEGF in small cell lung cancer patients. Anticancer Res, 30, 1773-8.
- Xue F, Wang L, Zhang M, Cai L (2011). Clinical significance of detection of serum values of neuron specific enolase before and after treatment for small cell lung cancer. Zhongguo Fei Ai Za Zhi, 14, 723-6.
- Yasasever V, Meral R, Camlica H, Duranyildiz D, Dalay N (1999). Serum NSE levels in the Turkish population. J Tumor Marker Oncology, 14, 35-40.
- Zhao X, Wang M (2011). Clinical utility of serum tumor markers in lung cancer. Zhongguo Fei Ai Za Zhi, 14, 286-91.
피인용 문헌
- Clinical Observations on the Association Between Diagnosis of Lung Cancer and Serum Tumor Markers in Combination vol.14, pp.7, 2013, https://doi.org/10.7314/APJCP.2013.14.7.4369
- The role of serum neuron-specific enolase in patients with prostate cancer: a systematic review of the recent literature vol.33, pp.1, 2018, https://doi.org/10.5301/ijbm.5000286